{"id":885,"date":"2026-04-24T00:03:37","date_gmt":"2026-04-24T00:03:37","guid":{"rendered":"https:\/\/decodepeptides.com\/?product=metabolic-weight-loss-stack-bundle"},"modified":"2026-04-25T00:29:10","modified_gmt":"2026-04-25T00:29:10","slug":"metabolic-weight-loss-stack-bundle","status":"publish","type":"product","link":"https:\/\/decodepeptides.com\/de\/product\/metabolic-weight-loss-stack-bundle\/","title":{"rendered":"Metabolische Gewichtsreduktionskombination \u2013 Retatrutid & MOTS-C"},"content":{"rendered":"
\n

Metabolic Weight Loss Stack \u2014 Retatrutide & MOTS-C: The Most Advanced Dual-Pathway Metabolic Research Protocol<\/h2>\n

The Stoffwechsel-Gewichtsverlust-Stack<\/strong> pairs Retatrutid<\/strong> \u2014 the first GIP\/GLP-1\/glucagon triple agonist to demonstrate over 24% body weight reduction in Phase II clinical trials, surpassing all previously tested pharmacological agents \u2014 with W\u00d6RTER-C<\/strong>, the mitochondria-encoded exercise mimetic that activates AMPK independently of the incretin axis. The combination creates a research model targeting metabolic dysfunction through two entirely separate molecular pathways: central neuroendocrine appetite suppression and energy expenditure<\/strong> (Retatrutide) and peripheral mitochondrial energy sensing and glucose disposal<\/strong> (MOTS-C).<\/p>\n\n

Retatrutide (LY3437943): The Triple Incretin Agonist<\/h2>\n

What Is Retatrutide?<\/h3>\n

Retatrutide (development code LY3437943) is a synthetic acylated peptide analogue engineered by Eli Lilly & Company as a triple agonist<\/strong> of three metabolic hormone receptors simultaneously: the GIP receptor (GIPR)<\/strong>, the GLP-1 receptor (GLP-1R)<\/strong>, and the glucagon receptor (GCGR)<\/strong>. It builds upon the dual GIP\/GLP-1 mechanism of tirzepatide (Mounjaro\/Zepbound) \u2014 itself the highest-performing approved weight loss drug \u2014 by adding glucagon receptor co-agonism, which expands metabolic effects to include dramatically increased energy expenditure and hepatic fat mobilisation, two mechanisms absent or weak in dual-agonist approaches.<\/p>\n

Mechanism of Action<\/h3>\n
    \n
  • GLP-1R agonism:<\/strong> In the hypothalamic arcuate (ARC) and paraventricular nuclei (PVN), GLP-1R activation suppresses appetite by reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP) \u2014 the primary orexigenic signals. In the gut, it slows gastric emptying, dramatically prolonging satiety duration. In pancreatic beta cells, it drives glucose-dependent insulin secretion with no hypoglycaemia risk at euglycaemia<\/li>\n
  • GIPR agonism:<\/strong> GIP receptors in adipose tissue and the CNS contribute to the overall weight loss effect when co-stimulated with GLP-1R \u2014 a synergy not yet fully mechanistically elucidated, but consistently demonstrated to exceed either agonist alone. GIP also modulates bone metabolism, kidney function, and cardiovascular physiology<\/li>\n
  • GCGR agonism \u2014 the key differentiator:<\/strong> Glucagon receptor activation drives hepatic glycogenolysis, increases fatty acid β-oxidation via CPT-1 upregulation, induces thermogenesis in brown adipose tissue (BAT) via UCP-1 (uncoupling protein-1), and activates a strong satiety signal through vagal afferents. Most critically, GCGR agonism significantly increases resting energy expenditure<\/strong> \u2014 addressing the metabolic adaptation (compensatory metabolic slowing) that limits long-term weight loss with appetite suppression alone<\/li>\n
  • Hepatic fat reduction:<\/strong> Via GCGR-driven cAMP elevation in hepatocytes, retatrutide markedly reduces liver fat (steatosis) \u2014 making it simultaneously the most potent pharmacological research tool for both obesity and non-alcoholic steatohepatitis (NASH) models<\/li>\n<\/ul>\n

    Phase II Clinical Trial Data<\/h3>\n

    Retatrutide has produced the most impressive Phase II weight loss data of any pharmacological agent in the history of obesity research:<\/p>\n

      \n
    • NEJM Phase II trial (2023):<\/strong> Adults with obesity receiving retatrutide 12mg weekly achieved a mean weight reduction of 24.2% of body weight<\/strong> at 48 weeks \u2014 surpassing semaglutide (~15%), tirzepatide (~22%), and approaching outcomes previously observed only with bariatric surgery (Jastreboff AM et al., 2023 \u2014 N Engl J Med<\/em>)<\/li>\n
    • Dose-response relationship:<\/strong> 4mg group: \u221217.5% body weight; 8mg group: \u221222.8%; 12mg group: \u221224.2%. Responder rate (≥5% loss) at highest dose: >96%<\/li>\n
    • Metabolic parameters:<\/strong> Fasting glucose \u221228 mg\/dL, HbA1c \u22121.6%, triglycerides \u221230%, blood pressure \u22124\/\u22123 mmHg; increased HDL cholesterol<\/li>\n
    • Lean mass preservation:<\/strong> Unlike severe caloric restriction, retatrutide maintained lean-to-fat mass ratio \u2014 a critical research variable for understanding quality of weight loss vs. quantity<\/li>\n
    • NASH model (Phase II):<\/strong> Significant reductions in liver fat content (MRI-PDFF) and fibrosis biomarkers, establishing retatrutide as the leading research compound for cardiometabolic-hepatic axis studies<\/li>\n
    • Type 2 diabetes:<\/strong> Landmark Lancet<\/em> 2023 trial: mean HbA1c reduction of 2.02% vs. 0.27% placebo at 24 weeks in T2D patients \u2014 with associated weight loss of 16.94% vs. 2.22% in placebo group (Rosenstock J et al., 2023 \u2014 Lancet<\/em>)<\/li>\n<\/ul>\n

      Retatrutide Research References<\/h3>\n
        \n
      1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial.” N Engl J Med<\/em>, 2023;389(6):514\u2013526.<\/li>\n
      2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet<\/em>, 2023;402(10401):529\u2013544.<\/li>\n
      3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab<\/em>, 2022;34(9):1234\u20131247.<\/li>\n
      4. Cusi K et al. “Retatrutide for NASH \u2014 Phase 2 results.” EASL Congress<\/em>, 2023.<\/li>\n<\/ol>\n\n

        MOTS-C: The Mitochondrial AMPK Activator<\/h2>\n

        What Is MOTS-C?<\/h3>\n

        MOTS-C (Mitochondrial Open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region<\/strong> \u2014 previously considered non-coding. Discovered in 2015 by Lee et al. at the University of Southern California, MOTS-C represents a fundamentally new paradigm in metabolic regulation: a retrograde mitochondrial-to-nuclear signal<\/strong> that coordinates systemic energy homeostasis in response to mitochondrial status. Its plasma levels decline with age and obesity, inversely correlating with insulin resistance, metabolic syndrome severity, and cardiovascular risk.<\/p>\n

        Mechanism of Action<\/h3>\n
          \n
        • AMPK activation via AICAR:<\/strong> MOTS-C inhibits MTHFD1 in the folate cycle, causing accumulation of AICAR<\/strong> (5-aminoimidazole-4-carboxamide ribonucleotide) \u2014 an endogenous AMP-mimetic that phosphorylates AMPK at Thr172 via LKB1 \u2014 functionally mimicking prolonged aerobic exercise at the molecular level<\/li>\n
        • Direct nuclear translocation:<\/strong> Under metabolic stress, MOTS-C translocates directly to the nucleus where it interacts with ARE (antioxidant response elements) via Nrf2 and suppresses NF-κB inflammatory signalling \u2014 a mechanism entirely independent of AICAR\/AMPK<\/li>\n
        • GLUT4 translocation:<\/strong> AMPK-dependent phosphorylation of TBC1D1 and AS160 drives GLUT4 vesicle fusion with the sarcolemma \u2014 increasing skeletal muscle glucose uptake independently of insulin receptor activation<\/li>\n
        • Enhanced β-oxidation:<\/strong> AMPK phosphorylates and inhibits ACC (acetyl-CoA carboxylase), reducing malonyl-CoA, relieving CPT-1 (carnitine palmitoyltransferase-1) inhibition, and dramatically increasing mitochondrial long-chain fatty acid import for β-oxidation<\/li>\n
        • mTORC1 suppression via TSC2\/Raptor:<\/strong> AMPK phosphorylates TSC2 and Raptor, suppressing mTORC1-driven anabolic signalling \u2014 the energetically expensive growth programme targeted by caloric restriction and rapamycin in longevity research<\/li>\n<\/ul>\n

          The Complementarity: Retatrutide + MOTS-C<\/h3>\n

          The two compounds in this stack are uniquely complementary because their mechanisms are parallel and non-overlapping<\/strong>:<\/p>\n

            \n
          • Retatrutide acts centrally<\/em> (hypothalamic appetite suppression), peripherally<\/em> on pancreatic beta cells and incretin receptors (GIPR, GLP-1R, GCGR), and in adipose\/liver tissue<\/li>\n
          • MOTS-C acts within skeletal muscle mitochondria<\/em> via AMPK \u2014 entirely independently of incretin signalling, GLP-1R, GIPR, or GCGR<\/li>\n
          • Combined: appetite suppression + increased energy expenditure (Retatrutide) + enhanced peripheral glucose disposal and fat oxidation (MOTS-C) \u2014 addressing all three components of the energy balance equation simultaneously<\/li>\n
          • MOTS-C’s muscle-protective AMPK activation may help preserve mitochondrial function and lean mass during the aggressive caloric deficit induced by retatrutide<\/li>\n<\/ul>\n

            MOTS-C Research References<\/h3>\n
              \n
            1. Lee C et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab<\/em>, 2015;21(3):443\u2013454.<\/li>\n
            2. Reynolds JC et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun<\/em>, 2021;12:470.<\/li>\n
            3. Kim KH et al. “MOTS-c peptide increases physical endurance and insulin sensitivity in aged mice.” Exp Mol Med<\/em>, 2019;51:1\u201312.<\/li>\n
            4. Lu H et al. “MOTS-c treatment attenuates inflammatory responses in the liver of aged mice.” Clin Interv Aging<\/em>, 2019;14:1775\u20131782.<\/li>\n<\/ol>\n\n

              Stack Comparison: Metabolic Pathway Coverage<\/h2>\n\n\n\n\n\n\n\n\n\n
              Parameter<\/th>\nRetatrutide Alone<\/th>\nMOTS-C Alone<\/th>\nCombined Protocol<\/th>\n<\/tr>\n<\/thead>\n
              Appetite suppression<\/td>\nStrong (GLP-1R\/GCGR central)<\/td>\nMinimal direct effect<\/td>\nStrong (Retatrutide-driven)<\/td>\n<\/tr>\n
              Energy expenditure<\/td>\nModerate-strong (GCGR\/BAT thermogenesis)<\/td>\nModerate (AMPK\/β-oxidation)<\/td>\nAdditive \u2014 dual mechanism<\/td>\n<\/tr>\n
              Insulin sensitivity<\/td>\nImproved (incretin-driven insulin secretion)<\/td>\nImproved (GLUT4\/AMPK \u2014 insulin-independent)<\/td>\nDual-pathway improvement<\/td>\n<\/tr>\n
              Mitochondrial function<\/td>\nLimited direct effect<\/td>\nStrong (retrograde mtDNA→nucleus signalling)<\/td>\nComplementary, MOTS-C-driven<\/td>\n<\/tr>\n
              Hepatic steatosis<\/td>\nStrong (GCGR-driven hepatic fat mobilisation)<\/td>\nModerate (AMPK → SREBP-1c suppression)<\/td>\nStrong dual-mechanism clearance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

              All products in this bundle are supplied for research purposes only. Not for human consumption. Not evaluated by any regulatory authority.<\/em><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

              The most advanced metabolic research combo: Retatrutide (triple incretin agonist, 24% weight loss in trials) + MOTS-C (mitochondrial exercise mimetic). Save 10%.<\/p>","protected":false},"featured_media":868,"comment_status":"open","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[56,59],"product_tag":[228,224,223,222,221,255,219],"class_list":["post-885","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-aging-longevity","product_cat-weight-management","product_tag-exercise-mimetic","product_tag-fat-oxidation","product_tag-glp-1-agonist","product_tag-insulin-sensitivity","product_tag-metabolic-health","product_tag-research-grade","product_tag-weight-loss","first","instock","shipping-taxable","product-type-grouped"],"_links":{"self":[{"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/product\/885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/comments?post=885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/media\/868"}],"wp:attachment":[{"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/media?parent=885"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/product_brand?post=885"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/product_cat?post=885"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/decodepeptides.com\/de\/wp-json\/wp\/v2\/product_tag?post=885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}